STADA and Alvotech Introduces Uzpruvo (Biosimilar, Stelara) Across the EU
Shots:
- The company has introduced Uzpruvo, biosimilar of Stelara (ustekinumab) across the EU to treat gastroenterology, dermatology & rheumatology indications. Uzpruvo is available in a pre-filled syringes with a thinner needle & is latex-free to avoid allergic reactions
- Further EU launches are expected in the upcoming mos., pending national price approvals through a fully European supply chain
- Uzpruvo was approved across the EU in Jan 2024 to treat adults with Crohn’s disease & psoriatic arthritis plus plaque psoriasis in adults & children (from 6yrs.)
Ref: Alvotech | Image: STADA
Related News:- STADA and Alvotech’s Uzpruvo (Biosimilar, Stelara) Obtains EC’s Approval for Immune-Mediated Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
